ESMO 2024: Updates on LEAP-012

Dose reductions of liposomal irinotecan and oxaliplatin did not compromise overall survival in patients with metastatic PDAC on NALIRIFOX.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

Certepetide plus chemotherapy showed signs of efficacy but failed to improve progression-free survival in metastatic PDAC in the ASCEND trial.

In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.

The combination of pelareorep and modified FOLFIRINOX with or without atezolizumab had an acceptable safety in newly diagnosed metastatic pancreatic ductal adenocarcinoma.

Zoldonrasib showed preliminary antitumor activity and manageable adverse events in KRAS G12D–mutated PDAC, per phase 1 trial data.